Renal-limited thrombotic microangiopathy (TMA) is a rare but serious condition that can lead to kidney failure if not promptly diagnosed and treated. In this case report, we present a case of renal-limited TMA induced by Fruquintinib, a novel anti-angiogenic agent used in the treatment of advanced colorectal cancer.
The patient in this case report is a 62-year-old male with a history of metastatic colorectal cancer who was started on Fruquintinib as part of his treatment regimen. After two weeks of treatment, the patient presented to the emergency department with complaints of fatigue, shortness of breath, and decreased urine output. Laboratory tests revealed elevated creatinine levels and signs of hemolysis, prompting further investigation.
A kidney biopsy was performed, which showed evidence of TMA characterized by thrombi in small blood vessels and damage to the kidney tissue. Further testing confirmed the presence of Fruquintinib in the patient’s system, leading to the diagnosis of renal-limited TMA induced by the medication.
Treatment for renal-limited TMA typically involves discontinuation of the offending agent and supportive care to manage symptoms and prevent further kidney damage. In this case, Fruquintinib was stopped, and the patient was started on dialysis to support his failing kidneys. With prompt intervention, the patient’s kidney function gradually improved, and he was able to discontinue dialysis after several weeks.
This case highlights the importance of recognizing and promptly addressing drug-induced TMA, as it can have serious consequences if left untreated. Healthcare providers should be aware of the potential for TMA with medications like Fruquintinib and monitor patients closely for signs and symptoms of the condition. Early detection and intervention are key to preventing long-term kidney damage and improving outcomes for patients with renal-limited TMA.
In conclusion, renal-limited TMA induced by Fruquintinib is a rare but potentially life-threatening condition that requires prompt recognition and treatment. Healthcare providers should be vigilant in monitoring patients on anti-angiogenic agents for signs of TMA and take appropriate action if symptoms arise. By being aware of this potential complication, healthcare providers can help ensure the safety and well-being of their patients undergoing treatment with these medications.
- The Renal Warrior Project. Join Now
- Source: Plato Data Intelligence.
- Source: https://renal.platohealth.ai/fruquintinib-induced-renal-limited-thrombotic-microangiopathy-a-case-report-bmc-nephrology/